Product Information
GLIMEPIRIDE 2 MG TABLET is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.0375 per EA under NDC 16571077450. Its NADAC has been published 219 times since Jul 27, 2022.
FDA first approved this application on Jun 29, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
16571077450
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
GLIMEPIRIDEApproval Type
Generic (ANDA)
FDA Application
ANDA202759FDA Approved
6/29/2012
TE Code
AB
On Market Since
6/29/2012
Pharmacological Classes
Price Statistics
The NADAC for GLIMEPIRIDE 2 MG TABLET has been published 219 times since Jul 27, 2022, and over the history we have for it it has risen 10.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0375 per EA |
|---|---|
| All-time high | $0.0408 (Jul 12, 2023) |
| All-time low | $0.0284 (Apr 17, 2024) |
| 52-week high | $0.0375 |
| 52-week low | $0.0295 |
| Median price | $0.0353 |
| Average price | $0.0348 |
| Largest weekly change | -26.3% (Apr 17, 2024) |
| Weeks tracked | 219 |
| Tracking since | Jul 27, 2022 |
Generic Alternatives
The matcher finds 10 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 5% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Glimepiride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Sulfonylurea class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GLIMEPIRIDE 2 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for GLIMEPIRIDE 2 MG TABLET, manufactured by Rising Pharma Holdings Inc., is $0.0375 per EA (NDC 16571077450), effective Sep 30, 2026.
How has the price of GLIMEPIRIDE 2 MG TABLET changed over time?
Over the history we have for it, the NADAC for GLIMEPIRIDE 2 MG TABLET has risen 10.4%. It has been tracked across 219 weekly CMS publications since Jul 27, 2022.
What are the highest and lowest recorded NADAC prices for GLIMEPIRIDE 2 MG TABLET?
Since Jul 27, 2022, the NADAC for GLIMEPIRIDE 2 MG TABLET has ranged from a low of $0.0284 (Apr 17, 2024) to a high of $0.0408 (Jul 12, 2023), with a median of $0.0353 per EA.
Are there cheaper alternatives to GLIMEPIRIDE 2 MG TABLET?
Yes. 10 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, GLIMEPIRIDE 2 MG TABLET, is $0.0358 per EA — about 5% below GLIMEPIRIDE 2 MG TABLET.
Who manufactures GLIMEPIRIDE 2 MG TABLET?
GLIMEPIRIDE 2 MG TABLET (NDC 16571077450) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.